Annual CFF
$22.32 M
-$1.76 M-7.33%
December 31, 2023
Summary
- As of February 8, 2025, SLS annual cash flow from financing activities is $22.32 million, with the most recent change of -$1.76 million (-7.33%) on December 31, 2023.
- During the last 3 years, SLS annual CFF has fallen by -$16.13 million (-41.95%).
- SLS annual CFF is now -60.12% below its all-time high of $55.95 million, reached on December 31, 2013.
Performance
SLS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$19.69 M
+$19.28 M+4656.04%
September 30, 2024
Summary
- As of February 8, 2025, SLS quarterly cash flow from financing activities is $19.69 million, with the most recent change of +$19.28 million (+4656.04%) on September 30, 2024.
- Over the past year, SLS quarterly CFF has increased by +$16.30 million (+481.51%).
- SLS quarterly CFF is now -52.31% below its all-time high of $41.28 million, reached on March 31, 2015.
Performance
SLS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$50.14 M
+$19.64 M+64.38%
September 30, 2024
Summary
- As of February 8, 2025, SLS TTM cash flow from financing activities is $50.14 million, with the most recent change of +$19.64 million (+64.38%) on September 30, 2024.
- Over the past year, SLS TTM CFF has increased by +$27.82 million (+124.67%).
- SLS TTM CFF is now -29.21% below its all-time high of $70.82 million, reached on September 30, 2013.
Performance
SLS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
SLS Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -7.3% | +481.5% | +124.7% |
| 3 y3 years | -42.0% | +10000.0% | +151.8% |
| 5 y5 years | -3.5% | +10000.0% | +151.8% |
SLS Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -7.3% | +84.8% | -26.1% | >+9999.0% | at high | +449.7% |
| 5 y | 5-year | -42.0% | +84.8% | -26.1% | >+9999.0% | at high | +470.8% |
| alltime | all time | -60.1% | +956.6% | -52.3% | +221.1% | -29.2% | +1922.5% |
SELLAS Life Sciences Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $19.69 M(+4656.0%) | $50.14 M(+64.4%) |
| Jun 2024 | - | $414.00 K(-98.4%) | $30.50 M(+1.5%) |
| Mar 2024 | - | $26.65 M(+686.9%) | $30.06 M(+34.7%) |
| Dec 2023 | $22.32 M(-7.3%) | $3.39 M(+6170.4%) | $22.32 M(+12.4%) |
| Sep 2023 | - | $54.00 K(-286.2%) | $19.86 M(-0.3%) |
| Jun 2023 | - | -$29.00 K(-100.2%) | $19.91 M(-53.6%) |
| Mar 2023 | - | $18.90 M(+1934.9%) | $42.94 M(+78.3%) |
| Dec 2022 | $24.08 M(+99.4%) | $929.00 K(+768.2%) | $24.08 M(+3.8%) |
| Sep 2022 | - | $107.00 K(-99.5%) | $23.20 M(-8.4%) |
| Jun 2022 | - | $23.00 M(>+9900.0%) | $25.34 M(+177.8%) |
| Mar 2022 | - | $47.00 K(-6.0%) | $9.12 M(-24.5%) |
| Dec 2021 | $12.07 M(-68.6%) | $50.00 K(-97.8%) | $12.07 M(-66.2%) |
| Sep 2021 | - | $2.24 M(-66.9%) | $35.70 M(-14.9%) |
| Jun 2021 | - | $6.78 M(+126.1%) | $41.95 M(+19.4%) |
| Mar 2021 | - | $3.00 M(-87.3%) | $35.14 M(-8.6%) |
| Dec 2020 | $38.44 M(+96.4%) | $23.68 M(+178.8%) | $38.44 M(+125.0%) |
| Sep 2020 | - | $8.49 M(<-9900.0%) | $17.09 M(+94.5%) |
| Jun 2020 | - | -$25.00 K(-100.4%) | $8.78 M(-62.8%) |
| Mar 2020 | - | $6.30 M(+171.7%) | $23.64 M(+20.8%) |
| Dec 2019 | $19.57 M(-15.4%) | $2.32 M(+1127.0%) | $19.57 M(+13.9%) |
| Sep 2019 | - | $189.00 K(-98.7%) | $17.17 M(-45.0%) |
| Jun 2019 | - | $14.83 M(+565.1%) | $31.24 M(+51.5%) |
| Mar 2019 | - | $2.23 M(-3034.2%) | $20.61 M(-10.9%) |
| Dec 2018 | $23.12 M(+317.8%) | -$76.00 K(-100.5%) | $23.12 M(+201.7%) |
| Sep 2018 | - | $14.25 M(+238.7%) | $7.66 M(-13.2%) |
| Jun 2018 | - | $4.21 M(-11.2%) | $8.83 M(-14.1%) |
| Mar 2018 | - | $4.74 M(-130.5%) | $10.27 M(+85.6%) |
| Dec 2017 | $5.53 M(-66.5%) | -$15.54 M(-200.8%) | $5.53 M(+15.0%) |
| Sep 2017 | - | $15.41 M(+172.6%) | $4.81 M(-26.3%) |
| Jun 2017 | - | $5.66 M(>+9900.0%) | $6.53 M(-337.4%) |
| Mar 2017 | - | $0.00(-100.0%) | -$2.75 M(-116.7%) |
| Dec 2016 | $16.50 M(-62.4%) | -$16.25 M(-194.9%) | $16.50 M(-48.0%) |
| Sep 2016 | - | $17.13 M(-572.2%) | $31.75 M(+129.1%) |
| Jun 2016 | - | -$3.63 M(-118.8%) | $13.86 M(-36.5%) |
| Mar 2016 | - | $19.25 M(-2007.9%) | $21.81 M(-50.3%) |
| Dec 2015 | $43.84 M | -$1.01 M(+32.9%) | $43.84 M(-19.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | -$759.00 K(-117.5%) | $54.70 M(-0.8%) |
| Jun 2015 | - | $4.33 M(-89.5%) | $55.13 M(+8.5%) |
| Mar 2015 | - | $41.28 M(+319.3%) | $50.82 M(+109.5%) |
| Dec 2014 | $24.26 M(-56.6%) | $9.85 M(-3129.5%) | $24.26 M(+9.8%) |
| Sep 2014 | - | -$325.00 K(-1810.5%) | $22.10 M(-63.3%) |
| Jun 2014 | - | $19.00 K(-99.9%) | $60.17 M(-14.8%) |
| Mar 2014 | - | $14.72 M(+91.5%) | $70.58 M(+26.1%) |
| Dec 2013 | $55.95 M(+31.8%) | $7.69 M(-79.6%) | $55.95 M(-21.0%) |
| Sep 2013 | - | $37.74 M(+261.8%) | $70.82 M(+111.8%) |
| Jun 2013 | - | $10.43 M(>+9900.0%) | $33.44 M(-17.2%) |
| Mar 2013 | - | $92.00 K(-99.6%) | $40.37 M(-4.9%) |
| Dec 2012 | $42.43 M(+121.1%) | $22.56 M(+6167.2%) | $42.43 M(+113.4%) |
| Sep 2012 | - | $360.00 K(-97.9%) | $19.88 M(-3.9%) |
| Jun 2012 | - | $17.36 M(+706.3%) | $20.70 M(+47.2%) |
| Mar 2012 | - | $2.15 M(>+9900.0%) | $14.06 M(-26.8%) |
| Dec 2011 | $19.20 M(+65.9%) | $10.00 K(-99.1%) | $19.20 M(+0.2%) |
| Sep 2011 | - | $1.17 M(-89.1%) | $19.16 M(+6.6%) |
| Jun 2011 | - | $10.72 M(+47.1%) | $17.97 M(+148.5%) |
| Mar 2011 | - | $7.29 M(<-9900.0%) | $7.23 M(-37.5%) |
| Dec 2010 | $11.57 M(+50.7%) | -$25.00 K(+66.7%) | $11.57 M(-0.1%) |
| Sep 2010 | - | -$15.00 K(-16.7%) | $11.58 M(-40.0%) |
| Jun 2010 | - | -$18.00 K(-100.2%) | $19.30 M(-0.1%) |
| Mar 2010 | - | $11.63 M(<-9900.0%) | $19.31 M(+151.5%) |
| Dec 2009 | $7.68 M(-3.1%) | -$16.00 K(-100.2%) | $7.68 M(-0.5%) |
| Sep 2009 | - | $7.71 M(<-9900.0%) | $7.72 M(<-9900.0%) |
| Jun 2009 | - | -$6000.00(+50.0%) | -$9000.00(-100.1%) |
| Mar 2009 | - | -$4000.00(-119.0%) | $7.92 M(-0.1%) |
| Dec 2008 | $7.92 M(-55.6%) | $21.00 K(-205.0%) | $7.92 M(+2.9%) |
| Sep 2008 | - | -$20.00 K(-100.3%) | $7.70 M(-15.0%) |
| Jun 2008 | - | $7.92 M(>+9900.0%) | $9.06 M(-46.0%) |
| Mar 2008 | - | $0.00(-100.0%) | $16.77 M(-6.0%) |
| Dec 2007 | $17.83 M(+744.4%) | -$204.00 K(-115.2%) | $17.83 M(-1.1%) |
| Sep 2007 | - | $1.34 M(-91.4%) | $18.04 M(+8.0%) |
| Jun 2007 | - | $15.63 M(+1367.6%) | $16.70 M(+1467.6%) |
| Mar 2007 | - | $1.06 M | $1.06 M |
| Dec 2006 | $2.11 M | - | - |
FAQ
- What is SELLAS Life Sciences annual cash flow from financing activities?
- What is the all time high annual CFF for SELLAS Life Sciences?
- What is SELLAS Life Sciences annual CFF year-on-year change?
- What is SELLAS Life Sciences quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for SELLAS Life Sciences?
- What is SELLAS Life Sciences quarterly CFF year-on-year change?
- What is SELLAS Life Sciences TTM cash flow from financing activities?
- What is the all time high TTM CFF for SELLAS Life Sciences?
- What is SELLAS Life Sciences TTM CFF year-on-year change?
What is SELLAS Life Sciences annual cash flow from financing activities?
The current annual CFF of SLS is $22.32 M
What is the all time high annual CFF for SELLAS Life Sciences?
SELLAS Life Sciences all-time high annual cash flow from financing activities is $55.95 M
What is SELLAS Life Sciences annual CFF year-on-year change?
Over the past year, SLS annual cash flow from financing activities has changed by -$1.76 M (-7.33%)
What is SELLAS Life Sciences quarterly cash flow from financing activities?
The current quarterly CFF of SLS is $19.69 M
What is the all time high quarterly CFF for SELLAS Life Sciences?
SELLAS Life Sciences all-time high quarterly cash flow from financing activities is $41.28 M
What is SELLAS Life Sciences quarterly CFF year-on-year change?
Over the past year, SLS quarterly cash flow from financing activities has changed by +$16.30 M (+481.51%)
What is SELLAS Life Sciences TTM cash flow from financing activities?
The current TTM CFF of SLS is $50.14 M
What is the all time high TTM CFF for SELLAS Life Sciences?
SELLAS Life Sciences all-time high TTM cash flow from financing activities is $70.82 M
What is SELLAS Life Sciences TTM CFF year-on-year change?
Over the past year, SLS TTM cash flow from financing activities has changed by +$27.82 M (+124.67%)